NANOVIRICIDES, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
NANOVIRICIDES, INC. (NNVC) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $6.07 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-28.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2017-09-28
- NANOVIRICIDES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2017 was $6.07M, a 23.38% decline from fiscal 2016.
- NANOVIRICIDES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $7.92M, a 46.62% increase from fiscal 2015.
- NANOVIRICIDES, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $5.40M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2017-06-30 | $6.07M 10-K · filed 2017-09-28 |
| 2016-06-30 | $7.92M 10-K · filed 2016-09-16 |
| 2015-06-30 | $5.40M 10-K · filed 2015-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |